Eventos supostamente atribuíveis à vacinação contra COVID-19 em crianças de uma estratégia da família

Sheila Ilda Eler Mourão; Cláudio Luiz Ferreira Júnior; Leandro Pinheiro Cintra; Josiane Moreira da Costa; Renata Aline de Andrade

doi:10.15343/0104-7809.202448e16492024P

Authors

Sheila Ilda Eler Mourão Universidade Federal dos Vales do Jequitinhonha e Mucuri - UFVJM. Diamantina/MG, Brasil. https://orcid.org/0009-0002-5311-2279
Cláudio Luiz Ferreira Júnior Universidade Federal dos Vales do Jequitinhonha e Mucuri - UFVJM. Diamantina/MG, Brasil. https://orcid.org/0000-0002-2994-5871
Leandro Pinheiro Cintra Faculdade de Medicina, Universidade Professor Edson Antônio Velano - UNIFENAS-BH. Belo Horizonte/MG, Brasil. https://orcid.org/0000-0002-0379-0146
Josiane Moreira da Costa Universidade Federal dos Vales do Jequitinhonha e Mucuri - UFVJM. Diamantina/MG, Brasil. https://orcid.org/0000-0001-6097-6994
Renata Aline de Andrade Universidade Federal dos Vales do Jequitinhonha e Mucuri - UFVJM. Diamantina/MG, Brasil. https://orcid.org/0000-0001-8604-938X

DOI:

https://doi.org/10.15343/0104-7809.202448e16492024P

Keywords:

COVID-19, Breakthrough Infections, Vaccination, Immunization, Immunization Programs, COVID-19 Vaccines

Abstract

COVID-19 in children can progress to more severe forms of the disease, such as severe acute respiratory syndrome and pediatric multisystem inflammatory syndrome. This study aimed to analyze Events Supposedly Attributable to Vaccination or Immunization (ESAVI) in the pediatric population. It was an exploratory, cross-sectional, and retrospective study conducted in the municipality of Conceição do Mato Dentro. Data were collected via telephone for 260 children vaccinated between January and July 2022 using the Ministry of Health's adverse events investigation form associated with the use of vaccines, serums, or immunoglobulin. Microarea 1 had the highest occurrence of ESAVI (4.23%); local pain was reported by 8.08% of vaccinated individuals, and Black children were 6.29 times more likely to present ESAVI. Promoting vaccine safety for COVID-19 has a crucial role in maintaining vaccination coverage rates and reducing illness rates.

Downloads

Download data is not yet available.

References

Leonor E, Lira P, Etereldes Goncalves Júnior, Simonelli K, Nascimento T, Zandonade E. COVID-19 in children in Espírito Santo State – Brazil. 2022 Jun 1;22(2):415–22. https://doi.org/10.1590/1806-9304202200020012.

Freitas MBA, Oliveira MS, Maciel IME. Adesão à Vacina Contra a Covid 19 pela comunidade acadêmica do UNIFUNEC. Ciências da Saúde e Biológicas. 4(7), 1–14. 2021. https://doi.org/10.24980/ucsb.v4i7.4838.

Brasil. Ministério da Saúde. Nota técnica no 255/2022-CGPNI/DEIDT/SVS/MS. Da atualização da terminologia de "Eventos Adversos Pós-Vacinação (EAPV)" para "Eventos Supostamente Atribuíveis à Vacinação ou Imunização (ESAVI). Brasília, DF: Ministério da Saúde, 2022. Disponível em: https://www.gov.br/saude/pt- br/vacinacao/esavi/notas-tecnicas/nt-255-2022-cgpni-deidt-svs-ms.pdf/ view. Acesso em: 06/02/2023.

Faria RM, Jantsch L, Neves ET, Hausen C, Barros APZ, et al. Social and territorial inequalities in the mortality of children and adolescents due to COVID-19 in Brazil. Revista Brasileira de Enfermagem. 75. 2022. https: //doi.org/10.1590/0034-7167-2021-0482.

Blanchard-Rohner G, Didierlaurent A, Tilmanne A, Smeesters P, Marchant A. Pediatric COVID-19: Immunopathogenesis, Transmission and Prevention. Vaccines. 2021 Sep 8;9(9):1002. https://doi.org/10.3390/vaccines9091002.

Silva HGA, Margotti BR, Marcon CEM. Eventos adversos pós-vacinais em pacientes imunizados contra a COVID-19 em um município do sul de Santa Catarina no ano de 2021. Medicina. 2023 Aug 15;56(2). DOI: 10.11606/issn.2176-7262.rmrp.2023.203651.

Sociedade Brasileira de Pediatria. Vacinas COVID-19 em crianças no Brasil: Uma questão prioritária de saúde pública. Sociedade Brasileira de Pediatria, v. 20, p. 1–11, 2021.

Soeiro EMD, Penido MGMG, Palma LMP, Bresolin NL, Lima EJ da F, Koch VHK, et al. Os desafios da pandemia e a vacinação covid-19 na população pediátrica com doenças renais. Brazilian Journal of Nephrology. 2022; 45: 244–51. DOI: 10.1590/2175-8239-jbn-2022- 0081pt.

Salvador PTCO, Alves KYA, Carvalho, KRS, Nehab MF, Camacho KG, Reis AT, et al. Inquérito online sobre os motivos para hesitação vacinal contra a COVID-19 em crianças e adolescentes do Brasil. Cadernos de Saude Publica [Internet]. 2023 Jan 1;39(10). https://doi. org/10.1590/0102-311XPT159122.

Sociedade Brasileira de Pediatria. Vacinas COVID-19 em crianças e adolescentes. [S. l.], 2023. Disponível em: https://www.sbp. com.br/especiais/pediatria-parafamílias/vacinas/vacinas-COVID-19-em-criancas-e-adolescentes/. Acesso em: 02/11/2023.

Moura ADA, Rouberte ESC, Lima FET, Chaves CS, Canto SVE, Lima GG de. Avaliação da Vigilância dos Eventos Adversos Pós Vacinação em um estado do nordeste brasileiro / Surveillance Assessment of Post-Vaccination Adverse Events in a Northeastern Brazilian State. Brazilian Journal of Health Review. 2020;3(6):16978–16793. DOI: 10.34119/bjhrv3n6-110.

Chagas SR, Dall’Agnol M, Pessoa AVC, Nascente E de P, Ramis-Vidal MG, Pascoal LM. Vacinas e suas reações adversas: revisão. Pubvet. 2019;13(8):1–14. https://doi.org/10.31533/pubvet.v13n8a398.1-14.

Silva BSBR, Santos WL. Reações adversas em vacinas: revisão integrativa. Revista JRG. 2022; 5(11):22-3. https://doi.org/10.5281/ zenodo.7109160.

Mahapatra S, Nagpal R, Marya C, Taneja P, Kataria S. Adverse events occurring post-covid-19 vaccination among healthcare professionals – A mixed method study. International Immunopharmacology. 2021 Nov;100:108136. https://doi.org/10.1016%2Fj. intimp.2021.108136.

Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. Elsevier. 2021. https://doi.org/10.1016/S1473-3099(20)30987-7.

Zheng YJ, Wang XC, Feng LZ, Xie ZD, Jiang Y et al. Expert consensus on COVID-19 vaccination in children. World J Pediatr. 2021 Oct;17(5):449-457. doi: 10.1007/s12519-021-00465-6. Epub 2021 Oct 7. PMID: 34618327; PMCID: PMC8494629. DOI: 10.1007/ s12519-021-00465-6.

Brandão LGVA et al. Eventos adversos pós-vacinação: desafios da vigilância e notificação. In: Silva TMR, Lima MG, (Orgs.). Estratégias de vacinação contra a COVID- 19 no Brasil: capacitação de profissionais e discentes de enfermagem. Brasília, DF: Editora Aben; 2021. P 104-12.

Sbors G, Peder LD. Eventos adversos pós-vacinação contra a COVID-19 em Lindoeste, no Paraná. RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218. 2022 Oct 13;3(10):e3102028. https://doi.org/10.47820/recima21.v3i10.2028.

Le Corre N, Abarca K, Astudillo P, Potin M, Sofía López, Macarena Goldsack, et al. Different Safety Pattern of an Inactivated SARS CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile. Vaccines. 2023 Sep 26;11(10):1526–6. https://doi.org/10.3390/vaccines11101526.

Xia S, Zhang Y, Wang Y, Wang H, Yang Y et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 Jan;21(1):39-51. doi: 10.1016/S1473- 3099(20)30831-8. Epub 2020 Oct 15. PMID: 33069281; PMCID: PMC7561304. DOI: 10.1016/S1473-3099(20)30831-8.

Kim MA, Lee YW, Kim SR, Kim JH, Min TK et al. COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group. Allergy Asthma Immunol Res. 2021 Jul;13(4):526-544. DOI: 10.4168/aair.2021.13.4.526. PMID: 34212542; PMCID: PMC8255352.

Laganà AS, Veronesi G, Ghezzi F, Ferrario MM, Cromi A, Bizzarri M, et al. Evaluation of menstrual irregularities after COVID-19 vaccination: Results of the MECOVAC survey. Open Medicine. 2022 Jan 1;17(1):475–84. DOI: 10.1515/med-2022-0452

Vasconcelos MMR, Aguiar FAR, Rodrigues DA, Albuquerque RAS, Martins KMC, Gomes FMA, et al. Análise das ocorrências de eventos adversos pós-vacinação | Global Academic Nursing Journal.. 2020. https://doi.org/10.5935/2675-5602.20200048.

Babatope T, Ilyenkova V, Marais D. COVID-19 vaccine hesitancy: a systematic review of barriers to the uptake of COVID-19 vaccine among adults in Nigeria. Bull Natl Res Cent. 2023;47(1):45. doi: 10.1186/s42269-023-01017-w. Epub 2023 Mar 21. PMID: 36970323; PMCID: PMC10028775. https://doi.org/10.1186/s42269-023-01017-w.

Santos LCB, Silva HS, Borja-Oliveira CR, Chubaci RYS, Gutierrez BAO. Eventos adversos pós-vacinação em idosos no Estado de São Paulo, Brasil, de 2015 a 2017. 2021 May 7. https://doi.org/10.1590/0102-311X00084820.

Brasil. Ministério da Saúde. Ministério da Saúde reforça: vacinas são seguras e importantes contra COVID-19. Brasília, DF: Ministério da Saúde, 2023. Disponível em: https://www.gov.br/saude/pt-br/assuntos/saude-com-ciencia/noticias/2023/outubro/ministerio-da-saude-reforca-vacinas-sao-seguras-e-importantes-contra-COVID-19. Acesso em: 20/11/2023.

Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 2021 Jun. https://doi.org/10.1016/S1473-3099(21)00319-4.

Sociedade Brasileira dos Enfermeiros Pediatras. Posição da Sociedade Brasileira de Enfermeiros Pediatras sobre a vacinação infantil contra a COVID-19. Ver. Soc. Bras. Enferm. Ped. 2022; 22:eSOBEP2022005.

Events supposedly attributable to COVID-19 vaccination in children from a family health strategy

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

How to Cite

Issue

Section

License

Submit your article

Indexed in

Information